He estimates a pool of 1,400 T315i patients in the U.S. At $115,000 per year, Ariad's commercial market opportunity is $160 million.
Ariad will never reach $160 million in Iclusig sales, however, my investor source warns, because most of these patients won't be capable of tolerating Iclusig for very long. Ariad might compensate by jacking up the price of Iclusig, but again, my source is skeptical because of the criticism and blowback the company will get if it tries to charge more for a troubled drug.
@adamfeuerstein you are a big joke with your ignorant articles $CPRX— BuySellStocks (@RookieStocker) October 23, 2013Thank you, too! -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts